Details for Patent: 9,693,988
✉ Email this page to a colleague
Title: | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent |
Abstract: | An aqueous formulation for topical application to the skin comprising water, a water-miscible organic solvent, and benzoyl peroxide, wherein the concentration of the organic solvent is sufficient to provide a stable suspension of benzoyl peroxide in the aqueous formulation without the inclusion of a surfactant in the formulation, wherein the ratio of concentrations of water and organic solvent in the formulation is sufficient to maintain the benzoyl peroxide in saturated solubility in the formulation following, application to the skin, and wherein the concentration of benzoyl peroxide in the formulation is less than 5.0% and at least 1.0% w/w. The formulation may further contain a chemical compound in addition to benzoyl peroxide that is effective in the treatment of acne. The aqueous formulations of the invention are useful in the treatment of acne and acne rosacea. |
Inventor(s): | Chang; Yunik (Sonoma, CA), Dow; Gordon J. (Santa Rosa, CA) |
Assignee: | DOW PHARMACEUTICAL SCIENCES, INC. (Petaluma, CA) |
Filing Date: | Sep 13, 2012 |
Application Number: | 13/613,401 |
Claims: | 1. A method for treating acne comprising topically applying an effective amount of a surfactant-free aqueous suspension formulation comprising benzoyl peroxide in a concentration of 2.5% w/w and clindamycin phosphate in a concentration of 1.2% w/w once daily to acne affected skin of a patient in need thereof, wherein the efficacy of the application of the formulation when applied only once daily, in terms of reduction of acne inflammatory and non-inflammatory lesions, is similar to that obtained by twice daily application of a topical gel composition containing 5.0% benzoyl peroxide, 1% clindamycin, dioctyl sodium sulfosuccinate, and water. 2. The method of claim 1 wherein the benzoyl peroxide in the aqueous suspension formulation has an average particle size of 100 microns or less. 3. The method of claim 2 wherein the benzoyl peroxide has an average particle size of 1 to 50 microns. 4. The method of claim 3 wherein the average particle size is 2.5 to 30 microns. 5. The method of claim 1 wherein the clindamycin phosphate is in solution. 6. The method of claim 1 wherein the aqueous suspension formulation is a gel. 7. The method of claim 6 wherein the aqueous suspension formulation comprises a gelling agent selected from the group of carbomer, hydroxyethyl cellulose, and hydroxypropyl cellulose. 8. The method of claim 1, wherein the aqueous suspension formulation further comprises a water-miscible organic solvent. 9. The method of claim 8, wherein the water-miscible organic solvent is propylene glycol. 10. The method of claim 8 or 9, wherein the concentration of the organic solvent is 1 to 4 times the concentration of the benzoyl peroxide in the aqueous suspension formulation. 11. The method of claim 8 or 9, wherein the ratio w/w of water to organic solvent in the aqueous suspension formulation is at least 12:1. 12. The method of claim 10, wherein the ratio w/w of water to organic solvent in the aqueous suspension formulation is at least 12:1. |